Revvity, Inc. (RVTY) PB Ratio: 1.52
Is Revvity, Inc.’s P/B ratio high or low?
Revvity, Inc.'s P/B ratio of 1.52 is 29% below its 5-year average of 2.13, near the low end of its 5-year range (1.28–5.05).
2.18% above its 12-month average of 1.49.
RVTY PB Ratio Chart
RVTY Average PB Ratio Chart
RVTY Current vs Average PB Ratio Chart
RVTY PB Ratio Metrics
PB RATIO
1.52
PB RATIO AVG TTM
1.49
PB RATIO AVG 3Y
1.65
PB RATIO AVG 5Y
1.98
PB RATIO AVG 10Y
2.84
PB RATIO AVG 15Y
2.62
PB RATIO AVG 20Y
2.36
CURRENT VS TTM AVG
+2.18%
CURRENT VS 3Y AVG
-7.75%
CURRENT VS 5Y AVG
-23.27%
CURRENT VS 10Y AVG
-46.49%
CURRENT VS 15Y AVG
-42.01%
CURRENT VS 20Y AVG
-35.57%
RVTY Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 1.52 | 1.49 | 1.65 | 1.98 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 1.44 | 1.00 | 0.99 | 1.29 |
| Baxter International Inc. (BAX)vs › | $10.19B | 1.74 | 1.59 | 2.24 | 3.03 |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 3.10 | 2.97 | 4.39 | 6.28 |
| Solventum Corporation (SOLV)vs › | $12.91B | 2.63 | 3.03 | 3.37 | 3.37 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 3.08 | 2.64 | 2.83 | 4.00 |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 22.13 | 50.19 | 28.39 | 22.04 |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 1.59 | 1.74 | 2.16 | 2.35 |
| Tempus AI, Inc. (TEM)vs › | $8.51B | 20.97 | 28.71 | 69.07 | 69.07 |
| DaVita Inc. (DVA)vs › | $13.46B | N/A | 42.86 | 21.68 | 16.81 |
P/B vs. its own history
At 1.52, P/B is cheaper than usual, sitting higher than 16% of its 20-year history.
20-year low
0.83
median
2.13
20-year high
5.14
Book Value Analysis
P/B Ratio
1.52
Market Price / Book Value per Share
Revvity, Inc. PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. PB Ratio FAQ
- What is the P/B ratio for Revvity, Inc. (RVTY)?
- The P/B ratio for RVTY stock is 1.52.
- Is Revvity, Inc.'s P/B ratio high or low?
- Revvity, Inc.'s P/B ratio of 1.52 is 29% below its 5-year average of 2.13, near the low end of its 5-year range (1.28–5.05).
- What is the TTM average P/B ratio for Revvity, Inc. (RVTY)?
- The TTM average P/B ratio for RVTY stock is 1.49.
- What is the 3Y average P/B ratio for Revvity, Inc. (RVTY)?
- The 3Y average P/B ratio for RVTY stock is 1.65.
- What is the 5Y average P/B ratio for Revvity, Inc. (RVTY)?
- The 5Y average P/B ratio for RVTY stock is 1.98.
- What is the 10Y average P/B ratio for Revvity, Inc. (RVTY)?
- The 10Y average P/B ratio for RVTY stock is 2.84.
- What is the 15Y average P/B ratio for Revvity, Inc. (RVTY)?
- The 15Y average P/B ratio for RVTY stock is 2.62.
- What is the 20Y average P/B ratio for Revvity, Inc. (RVTY)?
- The 20Y average P/B ratio for RVTY stock is 2.36.
Revvity, Inc. PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-17 | 1.52 |
| 2026-06-16 | 1.58 |
| 2026-06-15 | 1.57 |
| 2026-06-12 | 1.55 |
| 2026-06-11 | 1.58 |
| 2026-06-10 | 1.58 |
| 2026-06-09 | 1.62 |
| 2026-06-08 | 1.56 |
| 2026-06-05 | 1.53 |
| 2026-06-04 | 1.59 |
| 2026-06-03 | 1.57 |
| 2026-06-02 | 1.56 |
| 2026-06-01 | 1.57 |
| 2026-05-29 | 1.63 |
| 2026-05-28 | 1.58 |
| 2026-05-27 | 1.51 |
| 2026-05-26 | 1.51 |
| 2026-05-22 | 1.51 |
| 2026-05-21 | 1.49 |
| 2026-05-20 | 1.48 |
| 2026-05-19 | 1.49 |
| 2026-05-18 | 1.49 |
| 2026-05-15 | 1.46 |
| 2026-05-14 | 1.50 |
| 2026-05-13 | 1.48 |
| 2026-05-12 | 1.55 |
| 2026-05-11 | 1.55 |
| 2026-05-08 | 1.58 |
| 2026-05-07 | 1.54 |
| 2026-05-06 | 1.55 |
| 2026-05-05 | 1.44 |
| 2026-05-04 | 1.35 |
| 2026-05-01 | 1.35 |
| 2026-04-30 | 1.35 |
| 2026-04-29 | 1.28 |
| 2026-04-28 | 1.33 |
| 2026-04-27 | 1.36 |
| 2026-04-24 | 1.35 |
| 2026-04-23 | 1.36 |
| 2026-04-22 | 1.47 |
| 2026-04-21 | 1.47 |
| 2026-04-20 | 1.45 |
| 2026-04-17 | 1.47 |
| 2026-04-16 | 1.40 |
| 2026-04-15 | 1.45 |
| 2026-04-14 | 1.46 |
| 2026-04-13 | 1.45 |
| 2026-04-10 | 1.40 |
| 2026-04-09 | 1.41 |
| 2026-04-08 | 1.41 |
| 2026-04-07 | 1.37 |
| 2026-04-06 | 1.38 |
| 2026-04-02 | 1.39 |
| 2026-04-01 | 1.37 |
| 2026-03-31 | 1.37 |
| 2026-03-30 | 1.32 |
| 2026-03-27 | 1.31 |
| 2026-03-26 | 1.36 |
| 2026-03-25 | 1.37 |
| 2026-03-24 | 1.37 |
| 2026-03-23 | 1.36 |
| 2026-03-20 | 1.34 |
| 2026-03-19 | 1.34 |
| 2026-03-18 | 1.33 |
| 2026-03-17 | 1.36 |
| 2026-03-16 | 1.35 |
| 2026-03-13 | 1.34 |
| 2026-03-12 | 1.32 |
| 2026-03-11 | 1.40 |
| 2026-03-10 | 1.41 |
| 2026-03-09 | 1.44 |
| 2026-03-06 | 1.43 |
| 2026-03-05 | 1.51 |
| 2026-03-04 | 1.54 |
| 2026-03-03 | 1.50 |
| 2026-03-02 | 1.49 |
| 2026-02-27 | 1.54 |
| 2026-02-26 | 1.55 |
| 2026-02-25 | 1.52 |
| 2026-02-24 | 1.52 |
| 2026-02-23 | 1.55 |
| 2026-02-20 | 1.60 |
| 2026-02-19 | 1.59 |
| 2026-02-18 | 1.56 |
| 2026-02-17 | 1.52 |
| 2026-02-13 | 1.53 |
| 2026-02-12 | 1.53 |
| 2026-02-11 | 1.61 |
| 2026-02-10 | 1.67 |
| 2026-02-09 | 1.64 |
| 2026-02-06 | 1.62 |
| 2026-02-05 | 1.59 |
| 2026-02-04 | 1.66 |
| 2026-02-03 | 1.61 |
| 2026-02-02 | 1.71 |
| 2026-01-30 | 1.74 |
| 2026-01-29 | 1.73 |
| 2026-01-28 | 1.77 |
| 2026-01-27 | 1.83 |
| 2026-01-26 | 1.83 |
| 2026-01-23 | 1.86 |
| 2026-01-22 | 1.88 |
| 2026-01-21 | 1.86 |
| 2026-01-20 | 1.79 |
| 2026-01-16 | 1.80 |
| 2026-01-15 | 1.84 |
| 2026-01-14 | 1.78 |
| 2026-01-13 | 1.76 |
| 2026-01-12 | 1.66 |
| 2026-01-09 | 1.67 |
| 2026-01-08 | 1.62 |
| 2026-01-07 | 1.64 |
| 2026-01-06 | 1.68 |
| 2026-01-05 | 1.63 |
| 2026-01-02 | 1.57 |
| 2025-12-31 | 1.54 |
| 2025-12-30 | 1.56 |
| 2025-12-29 | 1.55 |
| 2025-12-26 | 1.54 |
| 2025-12-24 | 1.54 |
| 2025-12-23 | 1.56 |
| 2025-12-22 | 1.56 |
| 2025-12-19 | 1.54 |
| 2025-12-18 | 1.54 |
| 2025-12-17 | 1.54 |
| 2025-12-16 | 1.54 |
| 2025-12-15 | 1.58 |
| 2025-12-12 | 1.60 |
| 2025-12-11 | 1.66 |
| 2025-12-10 | 1.65 |
| 2025-12-09 | 1.58 |
| 2025-12-08 | 1.59 |
| 2025-12-05 | 1.61 |
| 2025-12-04 | 1.64 |
| 2025-12-03 | 1.65 |
| 2025-12-02 | 1.64 |
| 2025-12-01 | 1.64 |
| 2025-11-28 | 1.67 |
| 2025-11-26 | 1.67 |
| 2025-11-25 | 1.69 |
| 2025-11-24 | 1.61 |
| 2025-11-21 | 1.57 |
| 2025-11-20 | 1.50 |
| 2025-11-19 | 1.47 |
| 2025-11-18 | 1.49 |
| 2025-11-17 | 1.45 |
| 2025-11-14 | 1.48 |
| 2025-11-13 | 1.49 |
| 2025-11-12 | 1.50 |
| 2025-11-11 | 1.51 |
| 2025-11-10 | 1.47 |
| 2025-11-07 | 1.45 |
| 2025-11-06 | 1.43 |
| 2025-11-05 | 1.48 |
| 2025-11-04 | 1.46 |
| 2025-11-03 | 1.45 |
| 2025-10-31 | 1.46 |
| 2025-10-30 | 1.42 |
| 2025-10-29 | 1.48 |
| 2025-10-28 | 1.50 |
| 2025-10-27 | 1.51 |
| 2025-10-24 | 1.54 |
| 2025-10-23 | 1.52 |
| 2025-10-22 | 1.49 |
| 2025-10-21 | 1.51 |
| 2025-10-20 | 1.48 |
| 2025-10-17 | 1.45 |
| 2025-10-16 | 1.46 |
| 2025-10-15 | 1.43 |
| 2025-10-14 | 1.42 |
| 2025-10-13 | 1.42 |
| 2025-10-10 | 1.37 |
| 2025-10-09 | 1.43 |
| 2025-10-08 | 1.43 |
| 2025-10-07 | 1.42 |
| 2025-10-06 | 1.45 |
| 2025-10-03 | 1.46 |
| 2025-10-02 | 1.42 |
| 2025-10-01 | 1.43 |
| 2025-09-30 | 1.36 |
| 2025-09-29 | 1.31 |
| 2025-09-26 | 1.31 |
| 2025-09-25 | 1.29 |
| 2025-09-24 | 1.31 |
| 2025-09-23 | 1.33 |
| 2025-09-22 | 1.34 |
| 2025-09-19 | 1.35 |
| 2025-09-18 | 1.37 |
| 2025-09-17 | 1.33 |
| 2025-09-16 | 1.33 |
| 2025-09-15 | 1.31 |
| 2025-09-12 | 1.29 |
| 2025-09-11 | 1.33 |
| 2025-09-10 | 1.28 |
| 2025-09-09 | 1.32 |
| 2025-09-08 | 1.34 |
| 2025-09-05 | 1.35 |
| 2025-09-04 | 1.33 |
| 2025-09-03 | 1.30 |
| 2025-09-02 | 1.37 |
| 2025-08-29 | 1.40 |
| 2025-08-28 | 1.39 |
| 2025-08-27 | 1.38 |
| 2025-08-26 | 1.42 |
| 2025-08-25 | 1.43 |
| 2025-08-22 | 1.46 |
| 2025-08-21 | 1.39 |
| 2025-08-20 | 1.43 |
| 2025-08-19 | 1.42 |
| 2025-08-18 | 1.40 |
| 2025-08-15 | 1.41 |
| 2025-08-14 | 1.39 |
| 2025-08-13 | 1.41 |
| 2025-08-12 | 1.37 |
| 2025-08-11 | 1.33 |
| 2025-08-08 | 1.35 |
| 2025-08-07 | 1.34 |
| 2025-08-06 | 1.34 |
| 2025-08-05 | 1.38 |
| 2025-08-04 | 1.39 |
| 2025-08-01 | 1.39 |
| 2025-07-31 | 1.38 |
| 2025-07-30 | 1.43 |
| 2025-07-29 | 1.49 |
| 2025-07-28 | 1.50 |
| 2025-07-25 | 1.63 |
| 2025-07-24 | 1.61 |
| 2025-07-23 | 1.57 |
| 2025-07-22 | 1.51 |
| 2025-07-21 | 1.43 |
| 2025-07-18 | 1.47 |
| 2025-07-17 | 1.50 |
| 2025-07-16 | 1.49 |
| 2025-07-15 | 1.51 |
| 2025-07-14 | 1.55 |
| 2025-07-11 | 1.60 |
| 2025-07-10 | 1.61 |
| 2025-07-09 | 1.58 |
| 2025-07-08 | 1.58 |
| 2025-07-07 | 1.55 |
| 2025-07-03 | 1.59 |
| 2025-07-02 | 1.59 |
| 2025-07-01 | 1.56 |
| 2025-06-30 | 1.52 |
| 2025-06-27 | 1.54 |
| 2025-06-26 | 1.56 |
| 2025-06-25 | 1.54 |
| 2025-06-24 | 1.52 |
| 2025-06-23 | 1.49 |
| 2025-06-20 | 1.50 |
| 2025-06-18 | 1.49 |
| 2025-06-17 | 1.48 |
| 2025-06-16 | 1.52 |
| 2025-06-13 | 1.47 |
| 2025-06-12 | 1.51 |
| 2025-06-11 | 1.51 |
| 2025-06-10 | 1.52 |
| 2025-06-09 | 1.46 |
| 2025-06-06 | 1.45 |
| 2025-06-05 | 1.42 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh